Beneficial Ownership Report · SCHEDULE 13G
Alector, Inc.
ALECNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Alector, Inc.
- Company CIK
- 0001653087
- Street
- 131 Oyster Point Blvd. Suite 600
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Statement details
- Security class
- Common Stock, $0.0001 par value per share
- Event date
- 10/19/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- RA Capital Management, L.P.
- Citizenship / organization
- DE
- Reporting person type
- IA · PN
- Aggregate amount owned
- 7,500,000.00
- Percent of class
- 5.1
- Sole voting power
- 0.00
- Shared voting power
- 7,500,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,500,000.00
Reporting person 2
- Name
- Peter Kolchinsky
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 7,500,000.00
- Percent of class
- 5.1
- Sole voting power
- 0.00
- Shared voting power
- 7,500,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,500,000.00
Reporting person 3
- Name
- Rajeev Shah
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 7,500,000.00
- Percent of class
- 5.1
- Sole voting power
- 0.00
- Shared voting power
- 7,500,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,500,000.00
Reporting person 4
- Name
- RA Capital Healthcare Fund, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 7,500,000.00
- Percent of class
- 5.1
- Sole voting power
- 0.00
- Shared voting power
- 7,500,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,500,000.00
Item 1
Issuer
Alector, Inc.
Principal executive office address
131 Oyster Point Blvd. Suite 600, South San Francisco, CA, 94080.
Item 2
Citizenship
RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") are: RA Capital Management, L.P. ("RA Capital") Peter Kolchinsky ("Dr. Kolchinsky") Rajeev Shah ("Mr. Shah") RA Capital Healthcare Fund, L.P. (the "Fund") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
Principal business or residence address
The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
Item 3
Not applicable indication
Y
Item 4
Percent of class
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Such percentage is based upon the sum of: (i) 111,656,919 shares of common stock outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 6, 2026 and (ii) 36,600,000 shares of common stock issued in the Issuer's public offering of equity securities that closed on October 19, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 16, 2026.
Amount beneficially owned
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Fund directly holds 7,500,000 shares of common stock of the Issuer. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of common stock of the Issuer reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
Sole voting power
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Shared voting power
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Sole dispositive power
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Shared dispositive power
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 99.1 Joint Filing Agreement
Signature 1
- Reporting person
- RA Capital Management, L.P.
- Signed
- /s/ Peter Kolchinsky
- Title
- By Peter Kolchinsky, Authorized Signatory
- Date
- 10/26/2026
Signature 2
- Reporting person
- Peter Kolchinsky
- Signed
- /s/ Peter Kolchinsky
- Title
- Peter Kolchinsky
- Date
- 10/26/2026
Signature 3
- Reporting person
- Rajeev Shah
- Signed
- /s/ Rajeev Shah
- Title
- Rajeev Shah
- Date
- 10/26/2026
Signature 4
- Reporting person
- RA Capital Healthcare Fund, L.P.
- Signed
- /s/ Peter Kolchinsky
- Title
- By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
- Date
- 10/26/2026
Filed exhibits
- JOINT FILING AGREEMENT ↗ex-99-10262026_081005.htm
Company context
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.